Indoco Remedies Limited

BSE:532612 Stock Report

Market Cap: ₹30.6b

Indoco Remedies Past Earnings Performance

Past criteria checks 1/6

Indoco Remedies has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 11.6% per year. Indoco Remedies's return on equity is 2.7%, and it has net margins of 1.8%.

Key information

13.4%

Earnings growth rate

13.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate11.6%
Return on equity2.7%
Net Margin1.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Indoco Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:532612 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2417,7323214,685875
30 Jun 2418,2237673,677980
31 Mar 2418,1739854,621972
31 Dec 2317,9581,0164,219979
30 Sep 2317,3561,1344,141936
30 Jun 2316,8691,2813,307866
31 Mar 2316,6861,4233,941810
31 Dec 2216,4961,5693,718766
30 Sep 2216,0841,6173,616738
30 Jun 2215,6221,5373,014764
31 Mar 2215,4081,5483,435746
31 Dec 2114,3681,3933,407714
30 Sep 2114,1101,3173,423716
30 Jun 2113,5241,1572,832660
31 Mar 2112,4159303,341597
31 Dec 2012,0847343,372573
30 Sep 2011,6545713,326529
30 Jun 2011,2983932,614488
31 Mar 2011,0662413,167497
31 Dec 1910,9093022,916488
30 Sep 1910,6402642,825483
30 Jun 1910,0711112,767494
31 Mar 199,684-292,721515
31 Mar 1810,4244122,637535
31 Mar 1710,9687712,605517
31 Mar 1610,0818192,141432
31 Mar 158,5708281,664217
31 Mar 147,3365802,616208

Quality Earnings: 532612 has a high level of non-cash earnings.

Growing Profit Margin: 532612's current net profit margins (1.8%) are lower than last year (6.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 532612's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: 532612's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 532612 had negative earnings growth (-71.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).

Return on Equity

High ROE: 532612's Return on Equity (2.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 23:07
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Indoco Remedies Limited is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
Sarabjit NangraAngel Broking Private Limited
Srivathsan RamachandranAvendus Spark